Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

8.36USD
4:00pm EDT
Price Change (% chg)

$-0.08 (-0.95%)
Prev Close
$8.44
Open
$8.49
Day's High
$8.52
Day's Low
$8.32
Volume
195,638
Avg. Vol
273,328
52-wk High
$14.34
52-wk Low
$6.93

SPPI.OQ

Chart for SPPI.OQ

About

Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States,... (more)

Overall

Beta: 1.33
Market Cap (Mil.): $506.63
Shares Outstanding (Mil.): 60.03
Dividend: 0.15
Yield (%): --

Financials

  SPPI.OQ Industry Sector
P/E (TTM): 12.09 47.13 37.76
EPS (TTM): 0.70 -- --
ROI: 14.27 -2.58 18.76
ROE: 17.27 -2.66 19.59
Search Stocks

Spectrum shares plunge as hospitals switch to cheaper colon cancer treatment

- Shares of Spectrum Pharmaceuticals Inc fell as much as 38 percent on Wednesday after the company forecast a steep drop in full-year revenue as hospitals increasingly opt for a generic colon cancer treatment over its biggest-selling drug, Fusilev.

13 Mar 2013

Spectrum shares plunge as hospitals switch to cheaper colon cancer treatment

March 13 - Shares of Spectrum Pharmaceuticals Inc fell as much as 38 percent on Wednesday after the company forecast a steep drop in full-year revenue as hospitals increasingly opt for a generic colon cancer treatment over its biggest-selling drug, Fusilev.

13 Mar 2013

BRIEF-Spectrum Pharma shares down 40 pct premarket

NEW YORK, March 13 - Spectrum Pharmaceuticals Inc : * Shares down 40 percent in premarket trading

13 Mar 2013

Generics seen halving Spectrum Pharma's full year Fusilev sales

- Spectrum Pharmaceuticals forecast a steep drop in full-year sales as it expects uptake of its biggest-selling product, colon cancer drug Fusilev, to significantly decline as cheaper generics re-enter the market.

12 Mar 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: S&P Capital IQ Factual Report
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks